Literature DB >> 16115128

Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.

Weina Chen1, Dan Jones, L Jeffrey Medeiros, Rajyalashmi Luthra, Pei Lin.   

Abstract

FLT3 gene mutations, either internal tandem duplication or point mutation type, are common in acute myeloid leukaemia (AML). We describe 21 AML cases with both types of gene mutations, so-called dual mutations, representing approximately 1% of all cases. Most newly diagnosed AML with FLT3 dual mutations had monocytic differentiation and a normal karyotype. Over the disease course, changes in FLT3 mutation status were seen in 89% of cases, and were associated with cytogenetic changes. We conclude that FLT3 dual mutations occur rarely in AML, and appear to be related to clonal evolution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115128     DOI: 10.1111/j.1365-2141.2005.05666.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Authors:  Aref Al-Kali; Jorge Cortes; Stefan Faderl; Dan Jones; Caroline Abril; Sherry Pierce; Mark Brandt; Hagop Kantarjian; Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

2.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Authors:  Betül Oran; Jorge Cortes; Amer Beitinjaneh; Hsiang-Chun Chen; Marcos de Lima; Keyur Patel; Farhad Ravandi; Xuemei Wang; Mark Brandt; Borje S Andersson; Stefan Ciurea; Fabio P Santos; Leandro de Padua Silva; Elizabeth J Shpall; Richard E Champlin; Hagop Kantarjian; Gautam Borthakur
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

3.  Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.

Authors:  Gautam Borthakur; Hagop Kantarjian; Keyur P Patel; Farhad Ravandi; Wei Qiao; Stefan Faderl; Tapan Kadia; Raja Luthra; Sherry Pierce; Jorge E Cortes
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

4.  Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.

Authors:  Brittany Knick Ragon; Naval Daver; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Tapan Kadia; Betul Oran; Maro Ohanian; Alessandra Ferrajoli; Naveen Pemmaraju; Hagop M Kantarjian; Gautam Borthakur
Journal:  Am J Hematol       Date:  2017-06-09       Impact factor: 10.047

5.  Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia.

Authors:  Sergej Konoplev; C Cameron Yin; Steven M Kornblau; Hagop M Kantarjian; Marina Konopleva; Michael Andreeff; Gary Lu; Zhuang Zuo; Rajyalakshmi Luthra; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Journal:  Leuk Lymphoma       Date:  2012-07-09

6.  Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

Authors:  Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

7.  Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Authors:  Gautam Borthakur; Jorge E Cortes; Elihu E Estey; Elias Jabbour; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Tapan Mahendra Kadia; Xuemei Wang; Keyur Patel; Rajyalakshmi Luthra; Charles Koller; Mark Brandt; Farhad Ravandi; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2014-07-21       Impact factor: 10.047

8.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

9.  Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.

Authors:  Sergej Konoplev; Xuelin Huang; Harry A Drabkin; Hartmut Koeppen; Dan Jones; Hagop M Kantarjian; Guillermo Garcia-Manero; Weina Chen; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

Review 10.  Structural and functional alterations of FLT3 in acute myeloid leukemia.

Authors:  Soheil Meshinchi; Frederick R Appelbaum
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.